Author

Judith Millard

Observed names: J M Millard, J Millard, J. Millard, Judith M. Millard, Millard, J, Millard, Judith

Observed institutions: GlaxoSmithKline (United Kingdom), Public Health England, GlaxoSmithKline (United States), Saint Michael's Medical Center, University of Colorado Anschutz, Wellcome Trust

OpenAlex ID: A5036018659

Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter

1993 · David A. Cooper, Jose M. Gatell, et al. · New England Journal of Medicine · 216

The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy???Naive HIV-1-Infected Patients

2003 · Amalia Rodriguez-French, Jack Boghossian, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 149

Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)

2007 · W. G. Nichols, H. M. Steel, et al. · Antimicrobial Agents and Chemotherapy · 147

Studies on heat inactivation of hepatitis A virus with special reference to shellfish: Part 1. Procedures for infection and recovery of virus from laboratory-maintained cockles

1987 · Judith Millard, Hazel Appleton, et al. · Epidemiology and Infection · 99

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1996 · M.H. St. Clair, J. Millard, et al. · Antiviral Research · 76

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

2003 · Robin Wood, Keikawus Arasteh, et al. · Antimicrobial Agents and Chemotherapy · 47

Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: The ASCENT (CCR102881) Study

2008 · the ASCENT study team, Judith Currier, et al. · Antiviral Therapy · 25

Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)*

2009 · P Yeni, A LaMarca, et al. · HIV Medicine · 15

A Phase II Trial of Dual Protease Inhibitor Therapy: Amprenavir in Combination With Indinavir, Nelfinavir, or Saquinavir

2001 · Joseph J. Eron, Richard Haubrich, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 15

Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection

2000 · Louise Pedneault, Cindy Brothers, et al. · Clinical Therapeutics · 15

A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients

2004 · R. Wood, J. Eron, et al. · Clinical Infectious Diseases · 11

Time for action on hepatitis B immunisation

1987 · E M Vandervelde, J M Millard, et al. · BMJ · 7

A Dose-Ranging Study to Evaluate the Antiretroviral Activity and Safety of Amprenavir Alone and in Combination with Abacavir in HIV-Infected Adults with Limited Antiretroviral Experience

2001 · Robert T Schooley, Nathan Clumeck, et al. · Antiviral Therapy · 6

Pharmacodynamics of 141W94 as determined by short term change in HIV RNA Influence of viral isolate baseline EC50

1997 · George L. Drusano, Brian M. Sadler, et al. · Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy · 4

Works count: 17

Citation count: 832

H-index: 11

I10-index: 11